Medicare’s Plan for Drug-Price Negotiation — The Importance of Defining Generic Entry
New England Journal of Medicine · 2023
DOI: 10.1056/nejmp2304289 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Stacie B Dusetzina und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Health Policy and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville (S.B.D.); the Depar…. Hauptthemen laut MEDLINE: Drugs, Generic, Medicare, Drug Costs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Health Policy and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville (S.B.D.); the Department of Health Care Policy, Harvard Medical School (N.L.K., H.A.H.),…
ORCID-Profile: Michelle M Mello
Zitieren
APA
Dusetzina, S. B., Keating, N. L., Huskamp, H. A., & Mello, M. M. (2023). Medicare’s Plan for Drug-Price Negotiation — The Importance of Defining Generic Entry. New England Journal of Medicine. https://doi.org/10.1056/nejmp2304289
Vancouver
Dusetzina SB, Keating NL, Huskamp HA, Mello MM. Medicare’s Plan for Drug-Price Negotiation — The Importance of Defining Generic Entry. New England Journal of Medicine. 2023. doi:10.1056/nejmp2304289
BibTeX
@article{Dusetzina2023,
author = {Dusetzina, Stacie B and Keating, Nancy L and Huskamp, Haiden A and Mello, Michelle M},
title = {Medicare’s Plan for Drug-Price Negotiation — The Importance of Defining Generic Entry},
journal = {New England Journal of Medicine},
year = {2023},
doi = {10.1056/nejmp2304289}
}
EUVIMED